Effects of AZD1775 on the PK substrates for CYP3A, CYP2C19, CYP1A2 and on QT interval in patients with advanced cancer

Trial Identifier: D6014C00006
Sponsor:AstraZeneca
Collaborator:
Quintiles, Inc.
NCTID:NCT03333824
Start Date:December 2017
Primary Completion Date: January 2019
Study Completion Date: January 2019
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

LanguageDescription
English Translation

Trial Locations

CountryLocation
United States of America, TX Dallas, TX, United States of America, 75251
United States of America, TX Houston, TX, United States of America, 77030
United States of America, MI Bingham Farms, MI, United States of America, 48025
United States of America, MI Detroit, MI, United States of America, 48202
United States of America, SC Greenville, SC, United States of America, 29605
United States of America, AZ Tucson, AZ, United States of America, 85724
United States of America, CA Los Angeles, CA, United States of America, 90048
United States of America, CA Pasadena, CA, United States of America, 91105
United States of America, NH Lebanon, NH, United States of America, 03756
United States of America, RI Providence, RI, United States of America, 02903
United States of America, OH Cincinnati, OH, United States of America, 45229
United States of America, MD Silver Spring, MD, United States of America, 20910
United States of America, IN Indianapolis, IN, United States of America, 46202